Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418498 | 1.00 | KLK7 (0.52) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL27032862 | 0.92 | HDAC1 (0.48) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL27128254 | 0.92 | HDAC1 (0.48) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL31348948 | 0.92 | HDAC1 (0.48) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL31348954 | 0.92 | HDAC1 (0.48) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL15883745 | 0.92 | HDAC1 (0.48) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL29554781 | 0.92 | HDAC1 (0.48) | KLK7KLK5MDM4TP53PTPN1 | |
| SCHEMBL2439000 | 0.89 | MDM4 (0.50) | MDM4TP53CASP3MDM2 | |
| SCHEMBL13163967 | 0.87 | CASP3 (0.57) | MDM4TP53CASP3MDM2 | |
| SCHEMBL119962 | 0.87 | TNF (0.56) | MDM4TP53PTPN1TNFCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | KLK7 4817/4885KLK5 4839/4885MDM4 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.